Compare CUE & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUE | VNRX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | 41 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 31.9M |
| IPO Year | 2017 | 2012 |
| Metric | CUE | VNRX |
|---|---|---|
| Price | $0.27 | $0.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $3.00 | $2.50 |
| AVG Volume (30 Days) | 442.9K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.14 | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,287,000.00 | $1,233,511.00 |
| Revenue This Year | N/A | $68.22 |
| Revenue Next Year | $25.00 | $382.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 69.16 | 59.10 |
| 52 Week Low | $0.23 | $0.17 |
| 52 Week High | $1.05 | $0.94 |
| Indicator | CUE | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.65 | 36.92 |
| Support Level | $0.27 | $0.17 |
| Resistance Level | $0.36 | $0.27 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 14.60 | 17.93 |
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.